Prevalence and genotypic characterization of human parvovirus B19 in hemophilia patients
Abstract
Background and Objectives: Parvovirus B19 (B19V) is usually transmitted through respiratory tract, but can also be received through blood transfusion. This study evaluated the seroprevalence, DNA existence, and circulating genotypes of B19V in hemophilia patients.
Materials and Methods: Serum samples of cases and controls were analyzed for B19V using ELISA and real-time PCR. Finally, obtained sequences were used for genotyping.
Results: Among cases, 3% were anti-B19V IgM positive and 47% were anti-B19V IgG positive and B19V DNA was detected in 16% of them. However, among controls, 38% were anti-B19V IgG positive (P>0.05) and 5% were B19V DNA positive (P= 0.019). Also ~13% of cases were positive and all of controls were negative for IgG avidity test (P= 0.029). Viral load in case group was higher than control group (P = 0.037).
Conclusion: Since hemophilia patients receive large amounts of blood factors, prevalence of B19V in these patients might be higher than normal subjects.
1. Reinheimer C, Allwinn R, Doerr HW, Wittek M. Seroepidemiology of parvovirus B19 in the Frankfurt am Main area, Germany: evaluation of risk factors. Infection 2010; 38: 381-385.
2. Dobec M, Juchler A, Flaviano A, Kaeppeli F. Prolonged parvovirus b19 viremia in spite of neutralizing antibodies after erythema infectiosum in pregnancy. Gynecol Obstet Invest 2007; 63: 53-54.
3. Agi E, Hojjatipour S, Namvar A, Bolhassani A. Impact of blood transfusion on the prevalence of HHpgV-1, HPgV-1, and B19V among Iranian HCV-infected patients with Hemophilia. J Pediatr Hematol Oncol 2020; 42(4): e213-e218.
4. Srivastava A, Brewer AK, Mauser‐Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19(1): e1-47.
5. Nikoozad R, Mahzounieh MR, Ghorani MR. Detection of parvovirus B19 infection in thalasemic patients in Isfahan province, Iran. Jundishapur J Microbiol 2015; 8(11): e26590.
6. Wu Cg, Mason B, Jong J, Erdman D, McKernan L, Oakley M, et al. Parvovirus B19 transmission by a high‐purity factor VIII concentrate. Transfusion 2005; 45: 1003-1010.
7. Colmegna I, Alberts-Grill N. Parvovirus B19: its role in chronic arthritis. Rheum Dis Clin North Am 2009; 35: 95-110.
8. Lunardi C, Tinazzi E, Bason C, Dolcino M, Corrocher R, Puccetti A. Human parvovirus B19 infection and autoimmunity. Autoimmun Rev 2008; 8:116-120.
9. Rezaei F, Sarshari B, Ghavami N, Meysami P, Shadab A, Salimi H, et al. Prevalence and genotypic characterization of Human Parvovirus B19 in children with measles‐and rubella‐like illness in Iran. J Med Virol 2016; 88: 947-953.
10. Stelma FF, Smismans A, Goossens VJ, Bruggeman CA, Hoebe CJPA. Occupational risk of human Cytomegalovirus and Parvovirus B19 infection in female day care personnel in the Netherlands; a study based on seroprevalence. Eur J Clin Microbiol Infect Dis 2009; 28: 393-397.
11. Suárez González A, Otero Guerra L, De La Guerra GV, La Iglesia Martínez Pd PD, Solís Sánchez G, Rodríguez Fernández A. Varicella and parvovirus B19 immunity among pregnant women in Gijon, Spain. Med Clin (Barc) 2002; 119: 171-173.
12. He M, Zhu J, Yin H, Ke L, Gao L, Pan Z, et al. Human immunodeficiency virus/human parvovirus B19 co-infection in blood donors and AIDS patients in Sichuan, China. Blood Transfus 2012; 10: 502-514.
13. Abarca K, Cohen BJ, Vial PA. Seroprevalence of parvovirus B19 in urban Chilean children and young adults, 1990 and 1996. Epidemiol Infect 2002; 128: 59-62.
14. Soltani S, Zakeri A, Tabibzadeh A, Zandi M, Ershadi E, Rezayat SA, et al. A literature review on the parvovirus B19 infection in sickle cell anemia and β-thalassemia patients. Trop Med Health 2020; 48: 96.
15. Siritantikorn S, Kaewrawang S, Siritanaratkul N, Theamboonlers A, Poovorawan Y, Kantakamalakul W, et al. The prevalence and persistence of human parvovirus B19 infection in thalassemic patients. Asian Pac J Allergy Immunol 2007; 25: 169-174.
16. Drago F, Ciccarese G, Broccolo F, Javor S, Parodi A. Atypical exanthems associated with parvovirus B19 (B19V) infection in children and adults. J Med Virol 2015; 87: 1981-1984.
17. Slavov SN, Kashima S, Pinto ACS, Covas DT. Human parvovirus B19: general considerations and impact on patients with sickle-cell disease and thalassemia and on blood transfusions. FEMS Immunol Med Microbiol 2011; 62: 247-262.
18. Zadsar M, Aghakhani A, Banifazl M, Kazemimanesh M, Tabatabaei Yazdi SM, Mamishi S, et al. Seroprevalence, molecular epidemiology and quantitation of parvovirus B19 DNA levels in Iranian blood donors. J Med Virol 2018; 90: 1318-1322.
19. Azzi A, Manaresi E, Zakrzewska K, De Santis R, Musiani M, Zerbini M. Antibody response to B19 parvovirus VP1 and VP2 linear epitopes in patients with haemophilic arthritis. J Med Virol 2004; 72: 679-682.
20. Lavrent'eva IN, Antipova AI, Semenov AV, Bichurina MA. Genotyping of parvovirus B19 isolates circulating in Northwestern Federal District of Russia. Zh Mikrobiol Epidemiol Immunobiol 2013; (6):36-43.
2. Dobec M, Juchler A, Flaviano A, Kaeppeli F. Prolonged parvovirus b19 viremia in spite of neutralizing antibodies after erythema infectiosum in pregnancy. Gynecol Obstet Invest 2007; 63: 53-54.
3. Agi E, Hojjatipour S, Namvar A, Bolhassani A. Impact of blood transfusion on the prevalence of HHpgV-1, HPgV-1, and B19V among Iranian HCV-infected patients with Hemophilia. J Pediatr Hematol Oncol 2020; 42(4): e213-e218.
4. Srivastava A, Brewer AK, Mauser‐Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19(1): e1-47.
5. Nikoozad R, Mahzounieh MR, Ghorani MR. Detection of parvovirus B19 infection in thalasemic patients in Isfahan province, Iran. Jundishapur J Microbiol 2015; 8(11): e26590.
6. Wu Cg, Mason B, Jong J, Erdman D, McKernan L, Oakley M, et al. Parvovirus B19 transmission by a high‐purity factor VIII concentrate. Transfusion 2005; 45: 1003-1010.
7. Colmegna I, Alberts-Grill N. Parvovirus B19: its role in chronic arthritis. Rheum Dis Clin North Am 2009; 35: 95-110.
8. Lunardi C, Tinazzi E, Bason C, Dolcino M, Corrocher R, Puccetti A. Human parvovirus B19 infection and autoimmunity. Autoimmun Rev 2008; 8:116-120.
9. Rezaei F, Sarshari B, Ghavami N, Meysami P, Shadab A, Salimi H, et al. Prevalence and genotypic characterization of Human Parvovirus B19 in children with measles‐and rubella‐like illness in Iran. J Med Virol 2016; 88: 947-953.
10. Stelma FF, Smismans A, Goossens VJ, Bruggeman CA, Hoebe CJPA. Occupational risk of human Cytomegalovirus and Parvovirus B19 infection in female day care personnel in the Netherlands; a study based on seroprevalence. Eur J Clin Microbiol Infect Dis 2009; 28: 393-397.
11. Suárez González A, Otero Guerra L, De La Guerra GV, La Iglesia Martínez Pd PD, Solís Sánchez G, Rodríguez Fernández A. Varicella and parvovirus B19 immunity among pregnant women in Gijon, Spain. Med Clin (Barc) 2002; 119: 171-173.
12. He M, Zhu J, Yin H, Ke L, Gao L, Pan Z, et al. Human immunodeficiency virus/human parvovirus B19 co-infection in blood donors and AIDS patients in Sichuan, China. Blood Transfus 2012; 10: 502-514.
13. Abarca K, Cohen BJ, Vial PA. Seroprevalence of parvovirus B19 in urban Chilean children and young adults, 1990 and 1996. Epidemiol Infect 2002; 128: 59-62.
14. Soltani S, Zakeri A, Tabibzadeh A, Zandi M, Ershadi E, Rezayat SA, et al. A literature review on the parvovirus B19 infection in sickle cell anemia and β-thalassemia patients. Trop Med Health 2020; 48: 96.
15. Siritantikorn S, Kaewrawang S, Siritanaratkul N, Theamboonlers A, Poovorawan Y, Kantakamalakul W, et al. The prevalence and persistence of human parvovirus B19 infection in thalassemic patients. Asian Pac J Allergy Immunol 2007; 25: 169-174.
16. Drago F, Ciccarese G, Broccolo F, Javor S, Parodi A. Atypical exanthems associated with parvovirus B19 (B19V) infection in children and adults. J Med Virol 2015; 87: 1981-1984.
17. Slavov SN, Kashima S, Pinto ACS, Covas DT. Human parvovirus B19: general considerations and impact on patients with sickle-cell disease and thalassemia and on blood transfusions. FEMS Immunol Med Microbiol 2011; 62: 247-262.
18. Zadsar M, Aghakhani A, Banifazl M, Kazemimanesh M, Tabatabaei Yazdi SM, Mamishi S, et al. Seroprevalence, molecular epidemiology and quantitation of parvovirus B19 DNA levels in Iranian blood donors. J Med Virol 2018; 90: 1318-1322.
19. Azzi A, Manaresi E, Zakrzewska K, De Santis R, Musiani M, Zerbini M. Antibody response to B19 parvovirus VP1 and VP2 linear epitopes in patients with haemophilic arthritis. J Med Virol 2004; 72: 679-682.
20. Lavrent'eva IN, Antipova AI, Semenov AV, Bichurina MA. Genotyping of parvovirus B19 isolates circulating in Northwestern Federal District of Russia. Zh Mikrobiol Epidemiol Immunobiol 2013; (6):36-43.
| Files | ||
| Issue | Vol 14 No 4 (2022) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijm.v14i4.10244 | |
| Keywords | ||
| Human parvovirus B19; Hemophilia; Seroprevalence; Blood transfusion; Blood disease; Iran | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Keshavarz M, Janati-Namin N, Arjeini Y, Mokhtari-Azad T, Rezaei F. Prevalence and genotypic characterization of human parvovirus B19 in hemophilia patients. Iran J Microbiol. 2022;14(4):568-573.
